Why are polyamines of interest to cancerologists?;Les polyamines presentent-elles un interet dans le traitement du cancer?

Medecine/Sciences

Volumn 12, Issue 6-7, 1996, Pages 745-755

  Seiler, Nikolaus ^c   Moulinoux, Jacques Philippe ^a,b,c  

^a CNRS   (France)

^b INSERM   (France)

^c Inst de Med Légale   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; POLYAMINE; POLYAMINE DERIVATIVE; PUTRESCINE; SPERMIDINE; SPERMINE; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; HUMAN; POLYAMINE METABOLISM;

VERTEBRATA;

EID: 0029998424     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/815     Document Type: Article

References (45)

1. Bachrach U, Heimer YM. The physiology of polyamines. Boca Raton, USA: CRC Press, 1988.
2. Marton LJ, Pegg AE. Polyamines as targets for therapeutic intervention. Annu Rev Pharmacol Toxicol 1995 ; 35 : 55-91.
3. McCann PP, Pegg AE, Sjoerdsma A. Inhibition of polyamine metabolism. Orlando, USA: Academic Press, 1987.
4. Levin VA, Prados MD, Yung WKA, Gleason MJ, Ictech S, Malec M. Treatment of recurrent gliomas with eflornithine. J Natl Cancer Inst 1992 ; 84: 1432-7.
5. Seiler N, Dezeure F. Polyamine transport in mammalian cells. Int J Biochem 1990 ; 22 : 211-8.
6. Sarhan S, Knōdgen B, Seiler N. The gastrointestinal tract as polyamine source for tumor growth. Anticancer Res 1989 ; 9 : 215-24.
7. Bardocz S. The role of dietary polyamimes. Eur J Clin Nutr 1993 ; 47 : 683-90.
8. Seiler N, Sarhan S, Mamont P, Casara P, Danzin C. Some biological consequences of S-adenosylmethionine decarboxylase inhibition by MDL 73.811. Life Chem Rep 1991 ; 9 : 51-162.
9. Byers TL, Wiest L, Wechter RS, Pegg AE. Effect of chronic 5′-((Z)-4-amino-butenyl) méthylamino-5′-deoxyadenosine (AbeAdo) treatment on polyamine and elF-5A metabolism in AbeAdo-sensitive and resistant L1210 murine leukemia cells. Biochem J 1993 : 115-21.
10. Regenass U, Mett H, Stanek J, Mueller M, Kramer D, Porter CW. A new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. Cancer Res 1994 ; 54 : 3210-7.
11. Ask A, Persson L, Heby O. Increased survival of L1210 leukemic mice by prevention of the utilization of extracellular polyamines. Studies using a polyamine-uptake mutant, antibiotics and a polyamine deficient diet. Cancer Lett 1992 ; 66 : 29-34.
12. Khan NA, Quemener V, Moulinoux J-Ph, Characterization of polyamine transport pathways. In : Carter C, ed The neuropharmacology of polyamines. London, UK : Academic Press, 1994 : 37-60.
13. Bergeron RJ, Neims AH, McManis JS, Hawthorne TR, Vinson JRT, Bortell R, Ingeno M.J. Synthetic polyamine analogues as antineoplastics. J Med Chem 1988 ; 31 : 1183-90.
14. Fukuchi J, Kashiwagi K, Kusama-Eguchi K, Terao K, Shirahata A, Igarashi K. Mechanism of the inhibition of cell growth by N1,N12-bis(ethyl)spermine. Eur J Biochem 1992 ; 209 : 689-96.
15. Albanese L, Bergeron C, Pegg AE. Investigations of the mechanism by which mammalian cell growth is inhibited by N1,N12-bis(ethyl)spermine. Biochem J. 1993 ; 291 : 131-7.
16. Fogel-Petrovich M, Shappell NW, Bergeron RJ, Porter CW. Polyamine and polyamine analog regulation of spermidine/spermine N1-acetyltranferase (SSAT) in MALME-3M human melanoma cells. J Biol Chem 1993 ; 268 : 19118-25.
17. Vertino PM, Beerman TA, Kelly EJ, Bergeron RJ, Porter CW. Selective cellular depletion of mitochondrial DNA by the polyamine analog N1,N12-bis(ethyl)spermine and its relationship to polyamine structure and function. Mol Pharmacol 1991 ; 39 : 487-94.
18. Prakash NJ, Bowlin TL, Edwards ML, Sunkara P.S., Sjoerdsma A. Antitumor activity of a novel synthetic polyamine analogue, N,N'-bis-(3-(ethylamino)-propyl)-1,7-heptanediamine : potentiation by polyamine oxidase inhibitors. Anticancer Res 1990 ; 10 : 1281-8.
19. Porter CW, Bernacki RJ, Miller J, Bergeron RJ. Antitumor activity of N1,N11-bis (ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action. Cancer Res 1993 ; 53 : 581-6.
20. Seiler N, Sarhan S, Grauffel C, Jones R, Knödgen B, Moulinoux JP. Endogenous and exogenous polyamines in support of tumor growth. Cancer Res 1990 ; 50 : 5077-83.
21. Hessels J, Kingma AW, Ferwerda H, Keij J, van den Berg GA, Muskiet FAJ. Microbial flora in the gastrointestinal tract abolishes cytostatic effets of α-difluoromethylornithine in vivo. Int J Cancer 1989 ; 43 : 1155-64.
22. Hessels J, Kingma AW, Muskiet FAJ, Seiler N. Growth inhibition of two solid tumors in mice, caused by polyamine depletion, is not attended by alterations in cell-cycle phase distribution. Int J Cancer 1991 ; 48 : 697-703.
23. Seiler N, Atanassov L. The natural polyamines and the imminue system. In : Jucker E, ed. Progress in drug research. Basel, Suisse : Birkhāuser 1994 ; 43 : 87-141.
24. Chamaillard L, Quemener V, Havouis R, Moulinoux JP. Polyamine deprivation stimulates natural killer cell activity in cancerous mice. Anticancer Res 1993 ; 13 : 1027-34.
25. Flescher E, Bowlin TL, Talal N. Regulation of IL-2 production by mononuclear cells from rheumatoid arthritis synovial fluids. Clin Exp Immunol 1992 ; 87 : 435-7.
26. Pegg AE, Shantz LM, Coleman C. Ornithine decarboxylase as a target for chemoprevention. J Cell Biochem 1995 ; 22 (suppl) : 132-8.
27. Meyskens FL, Gerner EW. Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer. J Cell Biochem 1995 ; 22 (suppl) : 126-31.
28. Porter CW, Jänne J. Modulation of antineoplastic drug action by inhibitors of poly-amine biosynthesis. In : McCan PP, Pegg AE, Sjoerdsma A, eds. Inhibition of polyamine metabolism. Orlando, USA : Academic Press, 1987 : 203-47.
29. Marton LJ. Effect of treatment with DNA-directed cancer chemotherapeutic agents after polyamine depletion. Pharmacol Ther 1987 ; 32 : 183-90.
30. Quemener V, Moulinoux JP, Havouis R, Seiler N. Polyamine deprivation enhances antitumoral efficacy of chemotherapy. Anticancer Res 1992 ; 12 : 1447-54.
31. Cipolla B, Blanchard Y, Chamaillard L, Quemener V, Guillé F, Havouis R, Moulinoux JP. In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low dose cyclophosphamide. Urol Res 1996 (sous presse).
32. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990 ; 9 : 267-82.
33. Takigawa M, Enomoto M, Nishida Y, Pan HO, Kinoshita A, Suzuki F. Tumor angiogenesis and polyamines : alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro. Cancer Res 1990 ; 50 : 4131-8.
34. Monte M, Klein S, Jasnis MA, Davel L, Algranati ID, Sacerdote de Lustig E. Inhibition of lymphocyte and tumor-induced angiogenesis by the administration of difluoromethylornithine. Cancer J 1993 ; 6 : 147-50.
35. 19F NMR spectroscopy. NMR Biomed 1988 ; 1 : 11-9.
36. Cullis PM, Green RE, Malone ME, Merson-Davies L, Weaver R. Targeting tumor cells with polyamine - drug conjugates. Biochem Soc Trans 1994 ; 22 : 402S.
37. Russell DH. Increased polyamine concentrations in the urine of human cancer patients. Nature 1971 ; 233 : 144-5.
38. Bachrach U. Polyamines as markers of malignancy. In : Jucker E, ed. Progress in drug research. Basel, Swiss : Birkhäuser, 1992 ; 39 : 9-33.
39. Marton LJ, Edwards MS, Levin VA, Lubich WP, Wilson CB. CSF polyamines : a new and important means of monitoring patients with medulloblastoma. Cancer 1981 ; 47 : 757-60.
40. Moulinoux JP, Quemener V, Khan NA. Biological significance of cirulating polyamines in oncology. Cell Mol Biol 1991 ; 37 : 773-83.
41. Behr J. L'éponge à protons : un moyen d'entrer dans une cellule auquel les virus n'ont pas pensé. médecine/sciences 1996 ; 12 : 56-9.
42. Auvinen M, Paasinen A, Andersson LA, Hölttä E. Ornithine decarboxylase activity is critical for cell transformation. Nature 1992 ; 360 : 355-8.
43. Madhubala R, Pegg AE. Inhibition of ornithine decarboxylase and S-adenosylmethionine decarboxylase synthesis by antisense oligodeoxynucleotides. Mol Cell Biochem 1992 ; 118 : 191-5.
44. Rudkin BB, Mamont PS, Seiler N. Decreased protein-synthetic activity is an early consequence of spermidine depletion in rat hepatoma tissue-culture cells. Biochem J 1984 ; 217 : 731-41.
45. Seiler N, Bolkenius FN, Rennert OM. Interconversion, catabolism and elimination of the polyamines. Med Biol 1981 ; 59 : 334-46.